Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: The advantage of heterozygosity for coding mutations

Journal of Infectious Diseases

Volumn 198, Issue 1, 2008, Pages 72-80

  Catano, Gabriel ^a   Agan, Brian K ^c,d,e,f   Kulkarni, Hemant ^a   Telles, Vanessa ^a   Marconi, Vincent C ^c,e,f   Dolan, Matthew J ^c,d,e,f,g   Ahuja, Sunil K ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^g BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MANNOSE BINDING LECTIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; SKIN TEST; VIRUS LOAD;

ADULT; ALLELES; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HETEROZYGOTE; HIV INFECTIONS; HIV-1; HUMANS; MANNOSE-BINDING LECTIN; MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TIME FACTORS;

EID: 46349101377     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588712     Document Type: Article

References (48)

1. Kaslow RA, Dorak T, Tang JJ. Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 2005; 191(Suppl 1): S68-77.
2. Gonzalez E, Bamshad M, Sato N, et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999; 96:12004-9.
3. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-40.
4. Mangano A, Gonzalez E, Dhanda R, et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001; 183:1574-85.
5. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-36.
6. Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin - a soluble pattern recognition molecule. Mol Immunol 2004; 41:113-21.
7. Takahashi K, Ezekowitz RA. The role of the mannose-binding lectin in innate immunity. Clin Infect Dis 2005; 41(Suppl 7):S440-4.
8. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol 2001; 38:133-49.
9. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180:86-99.
10. Arora M, Munoz E, Tenner AJ. Identification of a site on mannan-binding lectin critical for enhancement of phagocytosis. J Biol Chem 2001; 276:43087-94.
11. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996; 17:532-40.
12. Turner MW, Hamvas RM. Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2000; 2:305-22.
13. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155:3013-20.
14. Garred P, Madsen HO, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349:236-40.
15. Lipscombe RJ, Sumiya M, Hill AV, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992; 1:709-15.
16. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A. Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet 1994; 21:125-31.
17. Hoal-Van Helden EG, Epstein J, Victor TC, et al. Mannose-binding protein B allele confers protection against tuberculous meningitis. Pediatr Res 1999; 45:459-64.
18. Bernig T, Taylor JG, Foster CB, Staats B, Yeager M, Chanock SJ. Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection. Genes Immun 2004; 5:461-76.
19. Mombo LE, Lu CY, Ossari S, et al. Mannose-binding lectin alleles in sub-Saharan Africans and relation with susceptibility to infections. Genes Immun 2003; 4:362-7.
20. Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both? J Exp Med 2004; 199:1295-9.
21. Soborg C, Madsen HO, Andersen AB, Lillebaek T, Kok-Jensen A, Garred P. Mannose-binding lectin polymorphisms in clinical tuberculosis. J Infect Dis 2003; 188:777-82.
22. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998;161:3169-75.
23. Garred P, Madsen HO, Kurtzhals JA, et al. Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet 1992; 19:403-12.
24. Ezekowitz RA, Shi L, Fraser I, Takahashi K. The mannose-binding lectin: an infection susceptibility gene. Adv Exp Med Biol 2005; 560:99-103.
25. Hellemann D, Larsson A, Madsen HO, et al. Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients. Hum Mol Genet 2007; 16:3071-80.
26. Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol 2005; 42:145-52.
27. Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med 1989; 169:185-96.
28. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993; 7:1307-13.
29. Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 2000; 81:949 -55.
30. Ying H, Ji X, Hart ML, et al. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 2004; 20:327-35.
31. Maas J, de Roda Husman AM, Brouwer M, et al. Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. AIDS 1998; 12:2275-80.
32. Amoroso A, Berrino M, Boniotto M, et al. Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children. AIDS 1999; 13:863-4.
33. Mellors JW. Viral-load tests provide valuable answers. Sci Am 1998; 279:90-3.
34. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
35. + T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999; 103:192-9.
36. Szczepanik M, Akahira-Azuma M, Bryniarski K, et al. B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity. J Immunol 2003; 171:6225-35.
37. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995; 172:79-87.
38. Maas JJ, Roos MT, Keet IP, et al. In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. J Infect Dis 1998; 178:1024-9.
39. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993; 6:1248-57.
40. Gordin FM, Hartigan PM, Klimas NG, Zolla-Pazner SB, Simberkoff MS, Hamilton JD. Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. J Infect Dis 1994; 169:893-7.
41. Lipscombe RJ, Beatty DW, Ganczakowski M, et al. Mutations in the human mannose-binding protein gene: frequencies in several population groups. Eur J Hum Genet 1996; 4:13-9.
42. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001; 2:165-74.
43. Nadeau JH. Modifier genes and protective alleles in humans and mice. Curr Opin Genet Dev 2003; 13:290-5.
44. Ytting H, Jensenius JC, Christensen IJ, Thiel S, Nielsen HJ. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 2004; 39:674-9.
45. Nakagawa T, Kawasaki N, Ma Y, Uemura K, Kawasaki T. Antitumor activity of mannan-binding protein. Methods Enzymol 2003; 363:26-33.
46. Ma Y, Uemura K, Oka S, Kozutsumi Y, Kawasaki N, Kawasaki T. Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: mannan-binding protein dependent cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1999; 96:371-5.
47. Pastinen T, Liitsola K, Niini P, Salminen M, Syvanen AC. Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. AIDS Res Hum Retroviruses 1998; 14:695-8.
48. Boniotto M, Crovella S, Pirulli D, et al. Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. Genes Immun 2000; 1:346-8.